Tumour anti-vascular alpha therapy: A mechanism for the regression of solid tumours in metastatic cancer

Physics in Medicine and Biology

Volumn 52, Issue 13, 2007, Pages

  Allen, Barry J ^a,b   Raja, Chand ^a   Rizvi, Syed ^a   Song, Emma Y ^a,b   Graham, Peter ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOMA; METASTATIC CANCER; MICROMETASTASES; TARGETED ALPHA THERAPY (TAT); THERAPEUTIC MODALITY;

CELLS; ENERGY TRANSFER; RADIOTHERAPY; REGRESSION ANALYSIS; TUMORS;

ONCOLOGY;

MONOCLONAL ANTIBODY PENTATE BI 213; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALPHA RADIATION; ARTICLE; CANCER REGRESSION; CANCER THERAPY; CLINICAL TRIAL; DRUG RESPONSE; HUMAN; METASTASIS; PRIORITY JOURNAL; RADIATION DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; TUMOR VOLUME; TUMOUR ANTIVASCULAR ALPHA THERAPY;

ALPHA PARTICLES; BISMUTH; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; KINETICS; MELANOMA; NEOPLASM METASTASIS; RADIOISOTOPES; RADIOTHERAPY; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34250363163     PISSN: 00319155     EISSN: 13616560     Source Type: Journal    
DOI: 10.1088/0031-9155/52/13/L01     Document Type: Article

References (16)

1. Allen B J 1999 Can alpha-immunotherapy succeed where other systemic modalities have failed? Nucl. Med. Commun. 20 205-7
2. Allen B J, Rizvi S M and Tian Z 2001 Preclinical targeted alpha therapy for subcutaneous melanoma Melanoma Res. 11 175-82
3. Allen B J et al 2005 Intralesional targeted alpha therapy for metastatic melanoma Cancer Biol. Therapy 4 1318-24
4. Baluk P, Hashizume H and McDonald D M 2005 Cellular abnormalities of blood vessels as targets in cancer Curr. Opin. Genet. Dev. 15 102-11
5. Bumol T F and Reisfeld R A 1982 Unique glycoprotein-proteoglycan complex defined by MAb on human melanoma cells Proc. Natl Acad. Sci. USA 79 1245-9
6. Jurcic G J et al 2002 Targeted alpha-particle immunotherapy for myeloid leukaemia Blood 100 1233-9
7. Mothersill C 2001 Radiation-induced bystander effects: past history and future direction Radiat. Res. 155 759-67
8. Nilsson S, Larsen R H, Fosså S D, Balteskard L, Borch K W, Westlin J E, Salberg G and Bruland O S 2005 First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases Clin. Cancer Res. 11 4451-9
9. Ozerdem U, Monosov E and Stallcup W B 2002 NG2 proteoglycan expression by pericytes in pathological microvasculature Microvasc. Res. 63 129-34
10. Pouly S et al 1999 Expression of a homologue of rat NG2 on human microglia Glia 27 259
11. Raja C et al 2007 Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma Cancer Biol. Therapy at press
12. Rizvi S M A, Sarkar S, Goozee G and Allen B J 2000 Radioimmunoconjugates for targeted alpha therapy of malignant melanoma Melanoma Res. 10 281-9
13. Schlingemann R O et al 1990 Expression of a high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumours Am. J. Pathol. 136 1393-405
14. Schmidt D et al 2004 Phase 1 clinical study on alpha-therapy for non-Hodgkin lymphoma 4th Alpha-Immunotherapy Symp. ed A Morgenstern (Dusseldorf: ITU) pp 12
15. Siemann D W, Chaplin D J and Horsman M R 2004 Vascular-targeting therapies for treatment of malignant disease Cancer Biol. Therapy 100 2491-9
16. Zalutsky M R 2005 Current status of therapy of solid tumours: brain tumour therapy J. Nucl. Med. 46 151S-156S